Canaccord Genuity Reiterates Buy Rating on Hinge Health
Canaccord Genuity maintains its buy rating on Hinge Health, Inc. with a $76 price target, a 9.48% upside from the current price.
Key Points
- Canaccord Genuity maintained its buy rating on Hinge Health, Inc. (HNGE) with a $76 price target on June 15, 2026.
- Canaccord Genuity's $76 price target implies 9.48% upside from Hinge Health, Inc.'s ($HNGE) current $69.42 share price.
- Hinge Health, Inc. shares traded around $65.34, with a market cap of approximately $5.06 billion and a forward P/E of 20.04.
- Insiders made several trades in June 2026, including Gabriel Mecklenburg's planned sales totaling over 166,668 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Canaccord Genuity reiterated its buy rating for Hinge Health, Inc. (NYSE: HNGE), setting a price target of $76. The analyst Richard Close maintains a positive outlook on the company, which currently trades at $65.34.
Other Institutional Activity in Hinge Health
Insight Holdings Group, LLC holds 9,375,164 shares valued at approximately $361.5 million. Meanwhile, Deer Management Co. LLC added 2,633,707 shares, bringing its total to 2,633,707 shares worth about $101.6 million. RTW Investments, LP significantly increased its stake by 1,576,500 shares, reaching 1,930,000 shares valued at $74.4 million. Conversely, Bit Capital GmbH reduced its holdings by 1,006,304 shares, ending with 2,309,797 shares worth $89.1 million.
Hinge Health, Inc. Stock Down 20.5%
Shares of NYSE:HNGE traded near $65.34. Hinge Health has a market cap of approximately $5.06 billion, with a forward P/E ratio of 20.04. It has a 52-week low of $30.08 and a high of $66.9. The stock's 50-day moving average is $50.53, and the 200-day moving average is $47.62. The company has a current ratio of 1.30 and a quick ratio of 1.04, with a debt-to-equity ratio of 2.24.
$HNGE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its latest earnings report, Hinge Health recorded revenue of $646.3 million, reflecting a growth rate of 47.2%. Despite this, the company is not yet profitable, with a net margin of -78.95% and a return on equity of -136.00%. The next earnings announcement is expected on August 4, 2026.
Insider Buying and Selling at Hinge Health, Inc.
In June 2026, several insider transactions occurred at Hinge Health. Gabriel Mecklenburg executed planned sales of 83,334 shares at an average price of $60.22 and another 83,334 shares at no disclosed price. Additionally, on June 5, 2026, he sold 50,000 shares under a planned sale. Kristina Leslie purchased 3,837 shares at $52.12 on June 3, 2026.
Analysts Set New Price Targets
On June 15, 2026, Canaccord Genuity maintained its buy rating with a $76 price target. Other analysts, including Keybanc, RBC Capital, and Truist Securities, also maintained buy ratings with targets of $90, $75, and $85, respectively, indicating a strong consensus. The average target price is $76.8 among 15 analysts.
About Hinge Health, Inc.
Hinge Health, Inc. is a healthcare company headquartered in San Francisco, California. It focuses on creating a scalable health system using technology to deliver care. The company specializes in musculoskeletal system care, addressing issues like acute injuries, chronic pain, and post-surgical rehabilitation. Hinge Health's platform employs AI-powered motion tracking and a proprietary wearable device to offer personalized care, primarily serving self-insured employers. Founded in 2012, it is led by CEO Daniel A. Perez and employs about 1,437 people.
Bottom Line
Hinge Health, Inc. continues to attract attention with its innovative approach to healthcare, particularly in musculoskeletal care. The reiterated buy rating from Canaccord Genuity suggests confidence in its growth prospects. However, as with all 13F filings and analyst reports, these insights are backward-looking and may not reflect the current market dynamics.
Get Hinge Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $HNGE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.